Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Bari
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of written informed consent
Diagnosis of schizophrenia using the Structured Clinical Interview for Diagnosis for the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition
Male or female patients aged between 18 and 65 years
Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin test at enrollment
Able to understand and comply with the requirements of the study
Patients with a cut off value for PANSS more than 75
Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
Known intolerance or lack of response to quetiapine fumarate, as judged by the investigator
Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrollment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir
Use of any of the following cytochrome P450 inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids
Administration of a depot antipsychotic injection within one dosing interval before randomization
Patients treated with clozapine within 28 days before the enrollment
Substance or alcohol dependence at enrollment (except dependence in full remission, and except for caffeine or nicotine dependence)
Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrollment
Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment
Unstable or inadequately treated medical illness (e.g. diabetes, angina pectoris, hypertension) as judged by the investigator
Involvement in the planning and conduct of the study
Previous enrollment or randomization of treatment in the present study
Participation in another drug trial within 4 weeks prior to enrollment into this study or longer in accordance with local requirements
A patient with Diabetes Mellitus
An absolute neutrophil count of ¬1.5 x 109 per liter
Pre-existing Organic Mental Disorder or Mental Retardation.
